{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T17:46:55Z","timestamp":1763747215361,"version":"3.44.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research in Veterinary Science"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.rvsc.2013.04.003","type":"journal-article","created":{"date-parts":[[2013,4,28]],"date-time":"2013-04-28T15:45:15Z","timestamp":1367163915000},"page":"381-388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Characterization of the use of liraglutide for glycemic control in healthy and Type 1 diabetes mellitus suffering dogs"],"prefix":"10.1016","volume":"95","author":[{"given":"H.","family":"Oda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Ishioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Sako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rvsc.2013.04.003_b0005","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rvsc.2013.04.003_b0010","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1463-1326.2010.01196.x","article-title":"Lead-3 study group. Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes","volume":"12","author":"Bode","year":"2010","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.rvsc.2013.04.003_b0015","doi-asserted-by":"crossref","first-page":"580","DOI":"10.2337\/diacare.19.6.580","article-title":"Glucagonostatic actions and reduction of fasting hyperglecemia by exogenous glucagon-like peptide 1(7\u201336) amide in type 1 diabetic patients","volume":"19","author":"Creutzfeldt","year":"1996","journal-title":"Diabetes Care"},{"key":"10.1016\/j.rvsc.2013.04.003_b0020","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2337\/diab.44.9.1126","article-title":"Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects","volume":"44","author":"Deacon","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.rvsc.2013.04.003_b0025","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2337\/diabetes.53.5.1187","article-title":"One week\u2019s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes","volume":"53","author":"Degn","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.rvsc.2013.04.003_b0030","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1172\/JCI30076","article-title":"The role of gut hormones in glucose homeostasis","volume":"117","author":"Drucker","year":"2007","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.rvsc.2013.04.003_b0035","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.rvsc.2013.04.003_b0040","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000314690","article-title":"A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes","volume":"86","author":"Fakhoury","year":"2010","journal-title":"Pharmacology"},{"key":"10.1016\/j.rvsc.2013.04.003_b0165","series-title":"Canine and Feline Endocrinology and Reproduction","first-page":"486","article-title":"Diabetes mellitus","author":"Feldman","year":"2004"},{"key":"10.1016\/j.rvsc.2013.04.003_b0050","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1517\/13543784.2012.638282","article-title":"Novel GLP-1 receptor agonists for diabetes","volume":"21","author":"Garber","year":"2012","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.rvsc.2013.04.003_b0055","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2337\/db09-1414","article-title":"The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action","volume":"59","author":"Hare","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.rvsc.2013.04.003_b0060","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2310\/JIM.0b013e318279b7d6","article-title":"Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs","volume":"61","author":"Harrison","year":"2013","journal-title":"Journal of Investigative Medicine"},{"key":"10.1016\/j.rvsc.2013.04.003_b0065","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1476-5381.1993.tb13551.x","article-title":"Stimulation of insulin secretion and improvement of glucose tolerance in rat and dog by the P2y-purinoceptor agonist, adenosine-5\u2032-O-(2-thiodiphosphate)","volume":"109","author":"Hillaire-Buys","year":"1993","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.rvsc.2013.04.003_b0070","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1152\/ajpendo.00106.2005","article-title":"Exogenously imposed postprandial-like rises in systemic glucose and GLP-1 do not produce an incretin effect, suggesting an indirect mechanism of GLP-1 action","volume":"291","author":"Ionut","year":"2006","journal-title":"American Journal of Physiology Endocrinology and Metabolism"},{"key":"10.1016\/j.rvsc.2013.04.003_b0075","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1463-1326.2010.01197.x","article-title":"Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial","volume":"12","author":"Iwamoto","year":"2010","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.rvsc.2013.04.003_b0080","doi-asserted-by":"crossref","first-page":"424","DOI":"10.2337\/diabetes.51.2.424","article-title":"Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes","volume":"51","author":"Juhl","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.rvsc.2013.04.003_b0085","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1463-1326.2009.01194.x","article-title":"Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes","volume":"12","author":"Kaku","year":"2010","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.rvsc.2013.04.003_b0090","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2337\/dc11-0096","article-title":"Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function","volume":"34","author":"Kielgast","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.rvsc.2013.04.003_b0095","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1507\/endocrj.K09E-269","article-title":"Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes","volume":"57","author":"Lee","year":"2010","journal-title":"Endocrine Journal"},{"key":"10.1016\/j.rvsc.2013.04.003_b0100","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1210\/jcem-25-10-1317","article-title":"Intestinal factors in the control of insulin secretion","volume":"25","author":"McIntyre","year":"1965","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.rvsc.2013.04.003_b0105","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s11892-006-0034-7","article-title":"Incretins and the development of Type 2 diabetes","volume":"6","author":"Meier","year":"2006","journal-title":"Current Diabetes Reports"},{"key":"10.1016\/j.rvsc.2013.04.003_b0110","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s00125-005-1707-5","article-title":"Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes","volume":"48","author":"Mest","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.rvsc.2013.04.003_b0115","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s11259-008-9059-5","article-title":"Comparison of time-action profiles of insulin glargine and NPH insulin in normal and diabetic dogs","volume":"32","author":"Mori","year":"2008","journal-title":"Veterinary Research Communications"},{"key":"10.1016\/j.rvsc.2013.04.003_b0120","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"Nauck","year":"1986","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.rvsc.2013.04.003_b0125","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/BF00401145","article-title":"Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7\u201336 amide) in type 2 (non-insulin-dependent) diabetic patients","volume":"36","author":"Nauck","year":"1993","journal-title":"Diabetologia"},{"key":"10.1016\/j.rvsc.2013.04.003_b0130","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.rvsc.2010.07.001","article-title":"Time-action profiles of insulin detemir in normal and diabetic dogs","volume":"90","author":"Sako","year":"2011","journal-title":"Research in Veterinary Science"},{"key":"10.1016\/j.rvsc.2013.04.003_b0135","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11259-008-9193-0","article-title":"Serum glycated albumin: potential use as an index of glycemic control in diabetic dogs","volume":"33","author":"Sako","year":"2009","journal-title":"Veterinary Research Communications"},{"key":"10.1016\/j.rvsc.2013.04.003_b0140","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1177\/104063870802000517","article-title":"Diagnostic significance of serum glycated albumin in diabetic dogs","volume":"20","author":"Sako","year":"2008","journal-title":"Journal of Veterinary Diagnostic Investigation"},{"key":"10.1016\/j.rvsc.2013.04.003_b0145","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1530\/EJE-11-0330","article-title":"Liraglutide as additional treatment for type 1 diabetes","volume":"165","author":"Varanasi","year":"2011","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.rvsc.2013.04.003_b0150","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1210\/jc.2002-021053","article-title":"Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects","volume":"88","author":"Vilsb\u00f8ll","year":"2003","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.rvsc.2013.04.003_b0155","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1463-1326.2012.01579.x","article-title":"Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide","volume":"2","author":"Vilsb\u00f8ll","year":"2012","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.rvsc.2013.04.003_b0160","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.diabres.2011.02.030","article-title":"Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on plasma omentin-1 levels in patients with Type 2 diabetes mellitus","volume":"92","author":"Yan","year":"2011","journal-title":"Diabetes Research and Clinical Practice"}],"container-title":["Research in Veterinary Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003452881300129X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003452881300129X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T03:57:00Z","timestamp":1758513420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003452881300129X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S003452881300129X"],"URL":"https:\/\/doi.org\/10.1016\/j.rvsc.2013.04.003","relation":{},"ISSN":["0034-5288"],"issn-type":[{"type":"print","value":"0034-5288"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of the use of liraglutide for glycemic control in healthy and Type 1 diabetes mellitus suffering dogs","name":"articletitle","label":"Article Title"},{"value":"Research in Veterinary Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rvsc.2013.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}